(S)-3-ethyl-5-methylhexanoic acid | 1092653-35-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-3-ethyl-5-methylhexanoic acid
• 英文别名: (3S)-3-ethyl-5-methylhexanoic acid
• CAS: 1092653-35-4
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: QJYCGYPXTIJAQX-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-3-ethyl-5-methylhexanoic acid 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  铜催化的二烷基锌试剂与 α'-氧烯酮的对映选择性共轭加成。

  摘要：

  DOI：

  10.1002/chem.200801343
• 作为产物：
  描述：

  (S)-5-ethyl-2-triethylsilyloxy-2,7-dimethyloctan-3-one 在 ammonium cerium (IV) nitrate 作用下， 以 水 、 乙腈 为溶剂， 以95%的产率得到(S)-3-ethyl-5-methylhexanoic acid
  参考文献：
  名称：

  铜催化的二烷基锌试剂与 α'-氧烯酮的对映选择性共轭加成。

  摘要：

  DOI：

  10.1002/chem.200801343

文献信息

• PROCESS FOR THE PREPARATION OF PREGABALIN
  申请人：HIKAL LIMITED

  公开号：US20150344919A1

  公开（公告）日：2015-12-03

  The present invention provides an improved process for the preparation of a compound of formula (I), which comprises the steps of: formula (I), (a) reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) optionally in presence of salts of weak acid and weak base or weak base in a suitable solvent to get 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV); (b) reacting 2-cyano-5-methyl-hex-2-enoic acid alkyl ester of formula (IV) with a suitable cyanide source in water or in an organic solvent or mixture thereof to get 2-isobutylsuccinonitrile of formula (V); (c) obtaining optionally 2-isobutylsuccinonitrile of formula (V) by reacting isovaleraldehyde of formula (II) and alkyl cyanoacetate of formula (III) in presence of suitable cyanide source in water or in an organic solvent or mixture thereof in single step; (d) converting 2-isobutylsuccinonitrile of formula pa (V) to racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) with a genetically modified nitrilase enzyme (Nit pt 9N_56_2) in water or optionally with an organic co-solvent at appropriate pH and temperature; (e) converting racemic 3-cyano-5-methyl-hexanoic acid or salt thereof of formula (VI) to racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII) by treatment with alcohol (R3OH) and acidic catalyst or alkyl halide (R3X) in presence of a base in a suitable solvent or a mixture of solvents thereof; (f) obtaining (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) and (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) by enzymatic enantioselective hydrolysis in water or organic solvent or a mixture thereof from racemic alkyl 3-cyano-5-methyl-hexanoate of formula (VII); (g) obtaining optionally the compound of formula (VII) by racemizing unwanted (R)-3-cyano-5-methyl-hexanoic acid or salt thereof of formula (X) or substantially enriched (R)-3-cyano-5-methyl-hexanoic acid salt thereof of formula (X) in presence of a base in organic solvent or a mixture thereof; (h) converting (S)-alkyl 3-cyano-5-methyl-hexanoate of formula (VIII) to pregabalin of formula (I) by hydrolyzing ester group with suitable alkali or alkaline earth metal base followed by hydrogenation optionally in one pot in a solvent selected from water or other organic solvents or a mixture thereof in presence of a suitable hydrogenation catalyst.

  本发明提供了一种改进的制备化合物(I)的方法，包括以下步骤：式(I)，(a)在适当溶剂中，将式(II)异戊醛和式(III)烷基氰乙酸酯在弱酸和弱碱盐或弱碱的存在下反应，得到式(IV)的2-氰基-5-甲基-己-2-烯酸烷基酯；(b)将式(IV)的2-氰基-5-甲基-己-2-烯酸烷基酯与适当的氰化物源在水中或有机溶剂中或二者的混合物中反应，得到式(V)的2-异丁基琥珀酰腈；(c)通过在水中或有机溶剂中或二者的混合物中的单步反应，将式(II)异戊醛和式(III)烷基氰乙酸酯在适当的氰化物源的存在下反应，可选地获得式(V)的2-异丁基琥珀酰腈；(d)通过在水中或适当的pH和温度下，用一种基因改造的腈酶酶(Nit pt 9N_56_2)将式(V)的2-异丁基琥珀酰腈转化为外消旋3-氰基-5-甲基-己酸或其盐的式(VI)；(e)通过在适当溶剂或其混合物中，在碱的存在下，用醇(R3OH)和酸性催化剂或烷基卤化物(R3X)处理，将式(VI)的外消旋3-氰基-5-甲基-己酸或其盐转化为式(VII)的外消旋烷基3-氰基-5-甲基-己酸酯；(f)通过在水或有机溶剂或其混合物中，通过酶选择性立体选择性水解，从式(VII)的外消旋烷基3-氰基-5-甲基-己酸酯获得(S)-烷基3-氰基-5-甲基-己酸酯的式(VIII)和(R)-3-氰基-5-甲基-己酸或其盐的式(X)；(g)通过在有机溶剂或其混合物中，在碱的存在下，将不需要的(R)-3-氰基-5-甲基-己酸或其盐的式(X)或富集的(R)-3-氰基-5-甲基-己酸或其盐的式(X)外消旋化，可选地获得式(VII)的化合物；(h)通过在水或其他有机溶剂或其混合物中，在适当的氢化催化剂的存在下，将(S)-烷基3-氰基-5-甲基-己酸酯转化为式(I)的前列酸，首先用适当的碱或碱土金属碱水解酯基，然后在一个锅中进行氢化。
• PROCESS FOR PREPARATION OF PREGABALIN
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：US20140243412A1

  公开（公告）日：2014-08-28

  Aspects of the present invention relate to improved process for preparation of (R)(−)-3-(carbamoylmethyl)-5-methylhexanoic acid (R-CMHA) of the formula (II) or its pharmaceutically acceptable salts in the presence of a lewis acid, process for preparation of pregabalin using R-CMHA of the formula (II) or its pharmaceutically acceptable salts prepared according to the present invention and process for preparation of pregabalin with low amount of undesired impurity.

  本发明涉及改进的制备(R)(−)-3-(carbamoylmethyl)-5-methylhexanoic acid (R-CMHA) (II式)或其药学上可接受的盐的工艺，其中存在一种路易斯酸，在制备过程中使用经本发明制备的公式(II)或其药学上可接受的盐的R-CMHA，以及制备低量不良杂质的pregabalin的工艺。
• PREGABALIN IMMUNOASSAYS
  申请人：ARK Diagnostics, Inc.

  公开号：US20160282370A1

  公开（公告）日：2016-09-29

  Compounds and methods for use in detecting pregabalin in a sample suspected of containing pregabalin are disclosed. Pregabalin derivatives are described for producing pregabalin conjugates. A pregabalin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-pregabalin antibody. A pregabalin-detectable label conjugate may be used in a signal producing system in pregabalin assays.

  本发明涉及用于检测怀疑含有普鲁巴林样本的化合物和方法。本发明还描述了用于制备普鲁巴林共轭物的普鲁巴林衍生物。普鲁巴林免疫原载体共轭物可用作制备抗普鲁巴林抗体的免疫原。普鲁巴林可检测标记共轭物可用于普鲁巴林测定中的信号产生系统。
• Process and Intermediates for the Preparation of Pregabalin
  申请人：PFIZER IRELAND PHARMACEUTICALS

  公开号：US20160024540A1

  公开（公告）日：2016-01-28

  The invention provides processes for the manufacture of a compound of formula (I A ). The invention further provides improved methods for the conversion of the compound of formula (I A ) into pregabalin.

  本发明提供了一种制造式（IA）化合物的工艺。此外，本发明还提供了将式（IA）化合物转化为普拉帕林的改进方法。
• Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH
  申请人：Taylor, JR. Charles Price

  公开号：US20110039899A1

  公开（公告）日：2011-02-17

  Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of LUTS, other than urinary incontinence, associated with OAB and/or BPH.

  使用alpha-2-delta配体或其药学上可接受的衍生物制造药物，用于治疗与OAB和/或BPH相关的LUTS，除了尿失禁。